The Role of NLRP3 in The Prognosis and Immune Infiltrates of Skin Cutaneous Melanoma (SKCM)

Shaobo Wu  
Xi'an Jiaotong University

Qijuan Zang  
Xi'an Jiaotong University

Bingling Dai (dbl1412@xjtu.edu.cn)  
Xi'an Jiaotong University

Research article

Keywords: NLRP3, SKCM, Immune infiltrates, Lymphocyte, Biomarker

DOI: https://doi.org/10.21203/rs.3.rs-93268/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Skin cutaneous melanoma is one of most aggressive type of cancers worldwide. Therefore, the identification of SKCM biomarkers is of great importance. NLRP3 Inflammasome Complex Nodlike Receptor protein 3 (NLRP3) is one of the most characteristic inflammasomes belonging to the NLR protein family. This is the first time to use TCGA data to study NLRP3 expression in SKCM patients and its prognostic value, potential biological function, and impact on the immune system.

Methods

The expression of NLRP3 in SKCM was analyzed by GEPIA. We assessed the impact of NLRP3 on SKCM patient survival through the survival module. Then download the SKCM data set from TCGA. Logistic regression was used to analyze the correlation between clinical data and NLRP3 expression. Univariate survival rate and multivariate Cox analysis were used to compare several clinical features and survival rates. We also used CIBERSORT to investigate the association between NLRP3 and cancer immune infiltration. We used TIMER to investigate NLRP3 expression and collection of immune infiltration levels in SKCM, as well as cumulative survival in SKCM. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset. In addition, data from the HPA was used to validate the results.

Results

Univariate Logistic regression analysis showed that increased NLRP3 expression was significantly correlated with age, stage and tumor status. Specifically, NLRP3 expression level has significant positive correlations with infiltrating levels of B cell, CD4+ T cells, CD8+ T cells, Macrophages, Neutrophils and DCs in SKCM. GSEA revealed that NLRP3 is closely correlated with pathways in cancer. HPA showed that in tumor tissues, NLRP3 has higher levels of expression compared to normal tissues.

Conclusion

The discovery of NLRP3 as a new biomarker of SKCM helps to elucidate how changes in the immune environment promote the occurrence of cutaneous melanoma. Further analysis suggested that NLRP3 might be a predictor of SKCM prognosis.

Background

Skin cutaneous melanoma (SKCM) is a major public health problem worldwide, the mortality of SKCM patients is still increasing in many countries [1], it causes 55 500 deaths annually [2]. Therefore, early detection is very important, and the detection of early prognostic markers is important for SKCM patients. Recently, numerous studies have shown that the dysfunction of immune system plays a key role in the progression of SKCM [3, 4]. It has been demonstrated that tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in SKCM patients [5]. Therefore, immunotherapy is popular used for treating melanoma. HD IL-2 was the first systemic immunotherapy approved for patients with advanced melanoma but efficacy was observed in a select number of patients [6]. Thus, it is still necessary to find novel immune-related therapeutic targets in SKCM.

The NLRP3 inflammasome consists of NLRP3, ASC and caspase-1. NLRP3 is a key role of inflammation in the development and progression of various cancers. However, its exact role in tumorigenesis is unclear, recent studies have shown that the excessive expression of NLRP3 and structural activation could lead to a variety of cancer occurrence and development, including malignant melanoma, lung cancer and breast cancer. In an independent study, Melvyn et al showed that NLRP3 is an important suppressor of natural killer cell-mediated control of metastases and carcinogenesis[7]. However, the precise prognostic relevance of immune infiltration in cutaneous melanoma remained unclear.

Thus, we downloaded the data from The Cancer Genome Atlas (TCGA). Meanwhile, the correlation between NLRP3 and prognosis of SKCM was determined by Gene Expression Profiling Interactive Analysis (GEPIA) and COX regression analysis. In addition, CIBERSORT was used to detect the relative proportions of different types of tumor infiltrating immune cells (TIICs) to
investigate the relationship between NLRP3 and tumor infiltrating immune cells in SKCM [8]. The findings of this study help us shed light on a potential correlation as well as a possible mechanism between NLRP3 and tumor-immune interactions. Thus, NLRP3 had the potential to become a novel predictor to evaluate prognosis and immune infiltration for SKCM patients.

Materials And Methods

Data download and preprocessing

Gene expression profile and clinical information of SKCM patients, including 471 tumor samples and 1 normal sample, were acquired from the Cancer Genome Atlas (TCGA) (https://tcga-data.nci.nih.gov/tcga/), which serves as a public repository for archiving high-throughput microarray experimental data [9]. Subsequent processing excluded cases with insufficient or missing data on age, overall survival time, local invasion, lymph node metastasis, distant metastasis and TNM stage. Finally, 322 cases with eligible clinical information were devoted into Cox regression analysis.

NLRP3 expression and survival analysis of SKCM by GEPIA

The analysis of NLRP3 expression from TCGA database was conducted with the GEPIA website (http://gepia.cancer-pku.cn/). GEPIA is a public platform for analyzing the RNA sequencing expression data of 9,736 tumors and 8,587 normal samples from the TCGA and the GTEx projects [10]. We obtained samples from TCGA and used GEPIA to analyze the correlation between overall survival and NLRP3 expression in SKCM.

Immune infiltrates analysis

TIMER is a comprehensive resource for systematic analysis of immune infiltrates for diverse cancer types (https://cistrome.shinyapps.io/timer/) [11]. To approximate TIICs abundance, the TIMER database used TCGA data on 10,897 samples from 32 types of cancer. We evaluated NLRP3 expression in SKCM and its correlation with the abundance of TIICs, including B cells, CD4+ T cells, CD4+ T cells, macrophages, neutrophils and Dendritic cells by gene modules. TIMER produced a graph showing the effect of gene expression level on tumor purity [12].

Analysis of the relative abundance of TIICs

CIBERSORT (http://cibersort.stanford.edu/) [13] is an online analytical platform that has been widely accepted and it is used to analyze the relevance of correlation between gene expression and TIICs in tumor. This analysis can be used to characterize the heterogeneity of cells according to the gene expression profile of complex tissues [14]. Additionally, the results have been shown to be highly consistent with the basic truth estimates in various cancers [8]. Based on the gene annotation matrix of 22 immune cell subtypes provided by the CIBERSORT web platform, we calculated the P value of each sample according to the deconvolution algorithm. P < 0.05 were considered statistically significant [15]. Thus, it can be further analyzed. To assess the effect of NLRP3 expression, we used 471 samples from TCGA and divided them into half with low expression and half with high expression, and then used these data to make a violin diagram by R.

Gene set enrichment analysis

Gene set enrichment analysis (GSEA) is commonly used to assess whether a particular gene set is significantly different in any two biological states. In this study, GSEA was used to analyze the differential signaling pathways of the activation of NLRP3 low and high expression groups in SKCM patients. A sequence listing was subsequently generated based on the correlation of all genes with NLRP3 expression and it was performed 1000 times in this analysis. Thus, we use standardized enrichment scores to classify each phenotypic enrichment pathway. Absolute values of FDR < 0.05 or P < 0.05 were statistically significant.

The Human Protein Atlas

The Human Protein Atlas (https://www.proteinatlas.org/) [16, 17] which has both on mRNA and protein expression data on 44 different human tissues. The antibody-based protein profiling shows the protein expression level and location. Additionally, its
protein expression score is based on immunohistochemical data manually scored with regard to staining intensity (negative, weak, moderate or strong) and fraction of stained cells (<25%, 25-75% or >75%). Thus, we used intensity of the staining to evaluate the expression of the NLRP3 protein in skin tissues and SKCM.

**Statistical analysis**

Statistical data obtained by TCGA was combined by R3.6.3. Logistic regression was used to analyze the correlation between clinical data and NLRP3 expression. In addition, multivariate Cox analysis was used to assess the influence of NLRP3 expression and other pathological and clinical factors (age, gender, lymph node, distant metastasis, tumor status, and stage) on OS. $P$ value < 0.05 was set up as the cut-off criterion. Moreover, to detect the correlation between 22 types of immune cells, we made the correlation heatmap, a chart of the correlation between every two different immune cells in samples.

**Results**

**Patient characteristics and multivariate analysis**

NLRP3 expression was significantly higher in the SKCM compared to normal tissues (Log2FC < 1, $P$ value < 0.01) (Fig. 1a). Through GEPIA, we found that the reduced expression of NLRP3 was significantly related to low overall survival ($P = 0.0014$) (Fig. 1b) and advanced pathological stage ($P=0.00213$) (Fig. 1c). As shown in Table 1, univariate analysis using Cox regression revealed that some factors, including age (HR = 1.02, $P = 0.000$), pathological stage (HR = 1.57, $P = 0.000$), tumor status (HR = 1.57, $P = 0.000$) and lymph node status (HR = 1.59, $P = 0.000$) were significantly associated with overall survival. In multivariate analysis (Table 1, Fig. 1d), the worse tumor status and less lymph node metastasis were independent prognostic factors with good prognosis. Thus, up-regulated NLRP3 expression (HR = 0.86, $P = 0.188$) cannot be an independent prognostic factor.

**NLRP3 expression is associated with SKCM level of immune infiltration and cumulative survival**

Multiple studies reported high lymphocytic infiltration to be associated with better patient survival outcome. Therefore, we attempted to investigate whether the expression of NLRP3 was associated with immune infiltration of SKCM. We assessed the correlation between NLRP3 expression and the level of immune invasion by TIMER. What’s more, our results showed that NLRP3 expression was associated with a better prognosis and higher immune infiltration of SKCM. Moreover, the expression level of NLRP3 was negatively correlated with the infiltration level of B cells ($r = 0.235, P = 4.65e-07$), CD8$^+$ T cells ($r = 0.488, P = 1.53e-27$), CD4$^+$ T cells ($r = 0.337, P = 2.43e-13$), Macrophages ($r = 0.573, P = 5.79e-41$), Neutrophils ($r = 0.672, P = 9.40e-61$) and DCs ($r = 0.637, P = 4.16e-52$) in SKCM (Fig. 2a). The B cell, CD8$^+$ T cells, Neutrophils and DCs were related factors to the cumulative survival rate of SKCM over time (Fig. 2b). These results suggested that NLRP3 plays a key role in SKCM immune infiltration. Additionally, our findings strongly support the significant role of NLRP3 in immune infiltration.

**Difference in the proportion of immune infiltrating cells**

We filtered out samples with $P < 0.05$ from the results of 22 immune cell components in each sample that was obtained, and we divided the high and low expression groups based on the median NLRP3 expression. Then we used CIBERSORT to explore gene expression profiles of downloaded samples to infer the density of 22 types of immune cells. The CIBERSORT algorithm applied to the 22 immune cell subtypes helped assess differences in their expression levels in the high and low NLRP3 expression groups (Fig. 2c). Results showed that CD8$^+$ T cells and Macrophages M0 were main immune cells effected by NLRP3 expression. Additionally, we assessed possible correlations between 22 types of immune cells (Fig. 2d). As shown in Fig. 4d, the correlation heatmap reflected a higher correlation within the proportions of different TIIC subgroups. Positive correlations were shown in red, whereas negative correlations were shown in blue. As in the above analysis, CD8$^+$ T cells and Macrophages M0 were negatively correlated (-0.65). By contrast, Neutrophils and Mast cells activated presented a significant positive correlation (0.78).

**GSEA investigation of NLRP3**


GSEA revealed significant differences (FDR < 0.05 or \( P < 0.05 \)) in enrichment of GO terms and KEGG pathways in samples with high levels of NLRP3. We explored the potential biological functions of NLRP3 through GO Term and KEGG Pathway analysis. As shown in Table 2, KEGG pathway analysis showed eight pathways that had the strongest positive correlation with NLRP3 expression: calcium signaling pathway, glioma, NON-small cell lung cancer, pancreatic cancer, pathways in cancer, small cell lung cancer, T cell receptor signaling pathway and Toll like receptor signaling pathway. The four pathways with the strongest negative correlation were oxidative phosphorylation, parkinsons disease, huntingtons disease and RNA polymerase (Fig. 3a). GO annotation showed eight categories that were positively correlated with high levels of NLRP3: external side of plasma membrane, interleukin 6 production, negative regulation of immune system process, regulation of inflammatory response, regulation of leukocyte mediated immunity, regulation of T cell activation, T cell activation involved in immune response and tumor necrosis factor superfamily cytokine production. GO analysis also uncovered five negatively correlated categories: melanin metabolic process, mitochondrial gene expression, mitochondrial respiratory chain complex assembly, mitochondrial translation and oxidative phosphorylation (Fig. 3b). All these results indicated the potential role of NLRP3 in the development of SKCM.

**Immunohistochemical staining**

Using the Human Protein Atlas database (https://www.proteinatlas.org), we explored the IHC staining of NLRP3 in skin tissues and skin cutaneous melanoma tissues. Immunohistochemistry analysis available from the HPA showed that in SKCM, NLRP3 has higher levels of expression compared to normal skin tissues (Fig. 4).

**Discussion**

SKCM is a highly aggressive tumor with apparent lethality, recently developed immunotherapy has been applied for multiple cancers, including SKCM, and demonstrated its superiority in some context [18]. However, extensive prognostic heterogeneity among SKCM patients requires individualized treatment options, thus requiring effective prognostic stratification. There was new data suggesting that NLRP3 inflammasome polymorphisms are related to different malignancies such as colon cancer and melanoma [19]. The precise clinical function of NLRP3 in the role of the initiation and promotion of differing neoplasms also highlights the therapeutic potential of inflammasomes, and as prognostic markers. Inflammation and persistent infection may contribute to various human malignancies [20, 21]. Evidence has accrued on the role that inflammation has in cancer initiation, development, progression, angiogenesis and invasion [22, 23]. Moreover, inflammation may induce an immune response involving T cells, B cells, NK cells, DC, macrophages and neutrophils [24, 25]. In this study, we demonstrated for the first time the regulatory potential in immune microenvironment and prognostic significance of NLRP3 complex as a whole in SKCM.

Additionally, we found high expression of NLRP3 predicted good prognosis and the low expression of NLRP3 affected the clinical characteristics of tumor pathological stage, lymh node metastasis status, and primary tumor status. Moreover, we found that different immune markers and different levels of immune cell infiltration were associated with differences in NLRP3 expression in SKCM. Thus, to further investigate the possible mechanism of NLRP3 expression in SKCM and its relationship to clinical characteristics, we downloaded the current data from public database TCGA. Then we used CIBERSORT to detect the relative proportions of multiple tumor-infiltrating immune cells (TIIC) in the tumor microenvironment of SKCM patients. These findings may help us to further investigate the application value of NLRP3 in SKCM, and reveal the potential correlation and possible mechanism of NLRP3 expression and immune interaction in tumor microenvironment. Therefore, NLRP3 may be a new indicator to evaluate the prognosis and immune infiltration of SKCM patients.

The NLRP3 inflammasome comprises the sensor molecule NLRP3, the adaptor protein ASC, and pro-caspase 1 [26]. Xi-Chun Pan et al [27] found that TP had no influence on NLRP3 or ASC oligomerization, but that it could inhibit NLRP3 and ASC expression, as well as NLRP3-ASC interactions, to inhibit inflammasome assembly. Melanoma research demonstrated that the development of cancer cells was inhibited by reduced inflammasome and IL-1\( \beta \) expression [28]. Recent studies suggested that NLRP3 inflammasome up regulation may aggravate inflammatory responses in skin neoplasms. Mice models with NLRP3, caspase-1 and ASC adaptor deficiencies show protection against cancer progression [29, 30]. Others have reported that NLRP1
can activate caspase 2 and 9 in neoplasm cells resulting in tumorigenesis, but NLRP3 did not appear to be tumorigenic [31]. In our study, it's worth noting that the expression of NLRP3 in SKCM correlated with the level of immune infiltration. CIBERSORT analysis suggested that the expression of NLRP3 had a significant effect on the infiltration levels of B cells, neutrophils and T cells in the SKCM tumor microenvironment. Compared with the low expression group, the macrophage M0 of the high expression group was decreased. CD8\(^+\) T cells are key effectors of tumor cell destruction in a variety of cancers, its high proportion of infiltration correlates well with a good clinical prognosis [32, 33]. The presence of T cells in the tumor parenchyma is a characteristic of immunoinvasive tumors, highlighting the antitumor effect of antitumor antigen T cells in the immunosuppressive microenvironment [34, 35]. Increasing evidence indicated that defective T cells migrate into tumors, which is one of the drug resistance mechanisms of immunotherapy [36, 37]. In summary, our study found that the expression of NLRP3 may affect the composition ratio of B, T cell and macrophages in the immune microenvironment of SKCM tumor tissue, thus indirectly regulating immune monitoring and affecting tumor progression.

What's more, we explored the expression of NLRP3 that is associated with many known cancer processes and immune response pathways. It included calcium signaling pathway, glioma, NON-small cell lung cancer, pancreatic cancer, pathways in cancer, small cell lung cancer, T cell receptor signaling pathway and Toll like receptor signaling pathway. All these results suggested that NLRP3 may be used as a prognostic and therapeutic target not only in SKCM, but also in many cancers.

**Conclusion**

In conclusion, although the relationship between NLRP3 and SKCM has not been explained in detail, based on our results and previous studies on NLRP3, it was reasonable to believe that NLRP3 played a key role in the regulation and recruitment of SKCM immune-infiltrated cells. It will influence the development of the pathophysiological mechanisms of SKCM, especially the development of immune infiltration. We strongly recommended that further research be conducted on this topic to gradually refine the evidence for the biological effects of NLRP3. In conclusion, NLRP3 was a prognostic biomarker with potential application prospects, related to immune infiltration of SKCM, and may be a new target for regulating immunosuppression.

**Declarations**

**Acknowledgements**

Not applicable

**Authors’ contributions**

SBW and QJZ participated in the design of this study, and they both performed the statistical analysis. SBW carried out the study and collected important background information. QJZ drafted the manuscript. All authors read and approved the final manuscript.

**Funding**

Our study was supported by the Fundamental Research Funds for the Central Universities (xjj2018167), the National Science Foundation for Post-doctoral Scientists of China (Grant no. 2019M653670) and Natural Science Basic Research Plan in Shaanxi Province of China (Grant no. 2019JQ-596).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Ethics approval and consent to participate**

Not applicable.
Consent for publication
Not applicable.

Competing interests
The authors declare no conflict of interest.

References
1. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma in the era of molecular profiling. Lancet 2009, 374(9687):362-365.
2. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S: Melanoma. Lancet 2018, 392(10151):971-984.
3. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC et al: Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 2009, 106(48):20429-20434.
4. Selitsky SR, Mose LE, Smith CC, Chai S, Hoadley KA, Dittmer DP, Moschos SJ, Parker JS, Vincent BG: Prognostic value of B cells in cutaneous melanoma. Genome Med 2019, 11(1):36.
5. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF: Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012, 30(21):2678-2683.
6. Clark JI, Singh J, Ernstoff MS, Lao CD, Flaherty LE, Logan TF, Curti B, Agarwala SS, Taback B, Cranmer L et al: A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. J Immunother Cancer 2018, 6(1):76.
7. Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M: Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol 2013, 2013:823849.
8. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015, 12(5):453-457.
9. Blum A, Wang P, Zenklusen JC: SnapShot: TCGA-Analyzed Tumors. Cell 2018, 173(2):530.
10. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z: GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017, 45(W1):W98-W102.
11. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res 2017, 77(21):e108-e110.
12. Aran D, Sirota M, Butte AJ: Systematic pan-cancer analysis of tumour purity. Nat Commun 2015, 6:8971.
13. Xiong TF, Pan FQ, Liang Q, Luo R, Li D, Mo H, Zhou X: Prognostic value of the expression of chemokines and their receptors in regional lymph nodes of melanoma patients. J Cell Mol Med 2020, 24(6):3407-3418.
14. Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z: The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother 2017, 95:55-61.
15. Goletzke J, Herder C, Joslowski G, Bolzenius K, Remer T, Wudy SA, Roden M, Rathmann W, Buyken AE: Habitually higher dietary glycemic index during puberty is prospectively related to increased risk markers of type 2 diabetes in younger adulthood. Diabetes Care 2013, 36(7):1870-1876.
16. Pontén F, Schweng JM, Asplund A, Edqvist PH: The Human Protein Atlas as a proteomic resource for biomarker discovery. J Intern Med 2011, 270(5):428-446.
17. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S et al: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010, 28(12):1248-1250.
18. Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D: Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol 2017, 43(3):604-611.

19. Karki R, Man SM, Kanneganti TD: Inflammasomes and Cancer. Cancer Immunol Res 2017, 5(2):94-99.

20. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.

21. Hussain SP, Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007, 121(11):2373-2380.

22. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.

23. McAllister SS, Weinberg RA: Tumor-host interactions: a far-reaching relationship. J Clin Oncol 2010, 28(26):4022-4028.

24. Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R: Innate immune mediators in cancer: between defense and resistance. Immunol Rev 2016, 274(1):290-306.

25. de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6(1):24-37.

26. Fu C, Zhang X, Zeng Z, Tian Y, Jin X, Wang F, Xu Z, Chen B, Zheng H, Liu X: Neuroprotective Effects of Qingnao Dripping Pills Against Cerebral Ischemia via Inhibiting NLRP3 Inflammasome Signaling Pathway: In Vivo and In Vitro. Front Pharmacol 2020, 11:65.

27. Pan XC, Liu Y, Cen YY, Xiong YL, Li JM, Ding YY, Tong YF, Liu T, Chen XH, Zhang HG: Dual Role of Triptolide in Interrupting the NLRP3 Inflammasome Pathway to Attenuate Cardiac Fibrosis. Int J Mol Sci 2019, 20(2).

28. Dunn JH, Ellis LZ, Fujita M: Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett 2012, 314(1):24-33.

29. Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, Schneider P, Gross O, Tschopp J, Yazdi AS: Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A 2012, 109(45):18384-18389.

30. Guarda G, Zenger M, Yazdi AS, Schroder K, Ferrero I, Menu P, Tardivel A, Mattmann C, Tschopp J: Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011, 186(4):2529-2534.

31. Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, Shellman YG, Norris DA, Dinarello CA, Spritz RA et al: NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 2017, 36(27):3820-3830.

32. Joyce JA, Fearon DT: T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015, 348(6230):74-80.

33. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Crosina D, Gnjatic S, Ambrosone C et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005, 102(51):18538-18543.

34. Trujillo JA, Swis FR, Bao R, Luke JJ: T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 2018, 6(9):990-1000.

35. Woo SR, Corrales L, Gajewski TF: The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol 2015, 36(4):250-256.

36. Anderson KG, Stromnes IM, Greenberg PD: Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell 2017, 31(3):311-325.

37. Chen DS, Mellman I: Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541(7637):321-330.

Tables

Table 1 Correlation between overall survival and multivariable characteristics in TCGA patients.
| Parameter         | Univariate analysis | Multivariate analysis |
|-------------------|---------------------|-----------------------|
|                   | HR  | 95%CI  | P     | HR  | 95%CI  | P  |
| Age               | 1.02| 1.01-1.03| 0.000| 1.01| 1.00-1.03| 0.020|
| gender            | 1.05| 0.74-1.48| 0.794| 1.02| 0.72-1.46| 0.905|
| stage             | 1.57| 1.29-1.91| 0.000| 0.82| 0.57-1.18| 0.286|
| T classification  | 1.57| 1.32-1.87| 0.000| 1.54| 1.24-1.91| 0.000|
| N classification  | 1.59| 1.35-1.86| 0.000| 1.66| 1.30-2.13| 0.000|
| NLRP3             | 0.83| 0.66-1.04| 0.106| 0.86| 0.68-1.08| 0.188|

*Table 2* Gene sets enriched in phenotype.
| Gene set name                                      | NES     | NOM p-val | FDR q-val |
|--------------------------------------------------|---------|-----------|-----------|
| **High expression**                              |         |           |           |
| KEGG_CALCULATION_SIGNALING_PATHWAY               | 2.1069617 | 0         | 4.88E-04 |
| KEGG_GLIOMA                                      | 2.0191584 | 0         | 0.001337478 |
| KEGG_NON_SMALL_CELL_LUNG_CANCER                 | 2.0142043 | 0         | 0.001321252 |
| KEGG_PANCREATIC_CANCER                           | 2.2465017 | 0         | 0         |
| KEGG_PATHWAYS_IN_CANCER                          | 2.2282844 | 0         | 4.77E-05 |
| KEGG_SMALL_CELL_LUNG_CANCER                      | 1.9993234 | 0         | 0.001549201 |
| KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY           | 2.3618245 | 0         | 0         |
| KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY        | 2.4893427 | 0         | 0         |
| GOEXTERNAL_SIDE_OF_PLASMA_MEMBRANE                | 2.6949873 | 0         | 0         |
| GOINTERLEUKIN_6_PRODUCTION                        | 2.7184777 | 0         | 0         |
| GONEGATIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS   | 2.7642787 | 0         | 0         |
| GO_REGULATION_OF_INFLAMMATORY_RESPONSE           | 2.7052493 | 0         | 0         |
| GO_REGULATION_OF_LEUKOCYTE_MEDIATED_IMMUNITY    | 2.6305406 | 0         | 0         |
| GO_REGULATION_OF_T_CELL_ACTIVATION               | 2.685686  | 0         | 0         |
| GOT_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE  | 2.5701654 | 0         | 0         |
| GO_TUMOR_NECROSIS_FACTOR_SUPERFAMILY_CYTOKINE_PRODUCTION | 2.78174 | 0         | 0         |
| **Low expression**                               |         |           |           |
| KEGG_OXIDATIVE_PHOSPHORYLATION                   | -2.192871 | 0         | 3.50E-04 |
| KEGG_PARKINSONS_DISEASE                          | -2.0404372 | 0         | 0.003454411 |
| KEGG_HUNTINGTONS_DISEASE                         | -2.0444586 | 0         | 0.005181618 |
| KEGG_RNA_POLYMERASE                              | -1.9101619 | 0.007677543 | 0.008911205 |
| GO_MELANIN_METABOLIC_PROCESS                     | -2.1573868 | 0         | 6.30E-04 |
| GO_MITOCHONDRIAL_GENE_EXPRESSION                 | -2.1840587 | 0         | 4.39E-04 |
| GO_MITOCHONDRIAL_RESPIRATORY_CHAIN_COMPLEX_ASSEMBLY | -2.2938614 | 0         | 2.08E-04 |
| GO_MITOCHONDRIAL_TRANSLATION                     | -2.2089524 | 0         | 3.10E-04 |
| GO_OXIDATIVE_PHOSPHORYLATION                     | -2.2029662 | 0         | 3.33E-04 |

NES: normalized enrichment score; NOM: nominal; FDR: false discovery rate.

Figures
**Figure 1**

Survival outcome, expression difference analyzed by GEPIA and multivariate Cox analysis of NLRP3. 

a. Differential expression of NLRP3 in different disease state (Tumor and Normal). 

b. Survival curve of differential NLRP3 expression. 

c. Differential expression of NLRP3 in different pathological stages. 

d. The expression of NLRP3 and multivariate Cox analysis of clinicopathological factors.
Figure 2

NLRP3 expression was correlated with immune infiltration level and cumulative survival in SKCM. a NLRP3 expression level had significant positive correlation with infiltrating levels of B cell ($r = 0.235, P = 4.65e-07$), CD8$^+$ T cells ($r = 0.488, P = 1.53e-27$), CD4$^+$ T cells ($r = 0.337, P = 2.43e-13$), Macrophages ($r = 0.573, P = 5.79e-41$), Neutrophils ($r = 0.672, P = 9.40e-61$) and DCs ($r = 0.637, P = 4.16e-52$) in SKCM. b Cumulative survival was related to B cell, CD8$^+$ T cells, Neutrophils, DCs and NLRP3 expression in SKCM. c Proportion of 22 immune cells in NLRP3 expression group. d Correlation degree matrix of relative proportions of immune cells in microenvironment.
Figure 3

Gene function enrichment map. a GSEA results showed differential enrichment of genes in KEGG with NLRP3 expression. b GSEA results showed differential enrichment of genes in GO with NLRP3 expression.
Figure 4

Immunohistochemical comparison of NLRP3 in normal skin tissues and SKCM.